Nabi Xinhua

ORCID: 0000-0002-0456-1310
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ubiquitin and proteasome pathways
  • Immune cells in cancer
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer, Stress, Anesthesia, and Immune Response
  • Genomics, phytochemicals, and oxidative stress
  • Biosimilars and Bioanalytical Methods
  • Healthcare and Venom Research
  • Phagocytosis and Immune Regulation
  • Natural product bioactivities and synthesis
  • Peptidase Inhibition and Analysis
  • Glutathione Transferases and Polymorphisms
  • Glycosylation and Glycoproteins Research
  • Diet and metabolism studies
  • Metabolomics and Mass Spectrometry Studies
  • CAR-T cell therapy research
  • Cancer Mechanisms and Therapy
  • Ferroptosis and cancer prognosis

Xinjiang Medical University
2019-2022

The present study was designed to the protective effect of Ziziphora clinopodioides flavonoids (ZCF) against H2O2-induced oxidative stress in HUVEC cells. MTT assay carried out determine cell viability cells following pretreatment with ZCF. Fluorescent microscopy measurements were performed evaluate apoptosis Furthermore, effects ZCF on activities antioxidants superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT), malondialdehyde production (MDA) and lactic...

10.1016/j.biopha.2019.109156 article EN cc-by-nc-nd Biomedicine & Pharmacotherapy 2019-07-01

To investigate the effect and mechanism of osimertinib combined with bevacizumab on lung cancer through cell transplanted tumor animal experiments to provide theoretical basis for further clinical trials.Immunohistochemistry was used detect expression PD-L1 in vessels nonmetastatic adenocarcinoma metastatic adenocarcinoma. At same time, CD8 FoxP3 tissue detected. qRT-PCR HUVECs. The levels p-Akt p-ERK HUVECs treated were analyzed by Western blot. AKT blocked specific inhibitor Ly294002...

10.1155/2022/1531353 article EN Journal of Oncology 2022-06-23

Abstract Background Siglec-15 (S15) is a type-I transmembrane protein and considered new candidate of immune checkpoint inhibitor for cancer immunotherapy. Methods In the present study, we first constructed characterized chimeric S15-specific monoclonal antibody (S15-4E6A). Then, antitumor effectiveness modulatory role S15-4E6A in macrophages (mφs) were explored vitro vivo . Finally, underlying mechanism by which S15mAb inhibits LUAD was preliminarily explored. Results The results...

10.21203/rs.3.rs-1373618/v1 preprint EN cc-by Research Square (Research Square) 2022-02-23

10.13523/j.cb.2007017 article EN Zhongguo shengwu gongcheng zazhi 2021-01-14
Coming Soon ...